{"ticker": {"uuid": "b70b4f93-822d-4bf9-989f-35daa2c51bd3", "symbol": "AKBA", "name": "Akebia Ther", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPR1NQY19HM1p5QnpOUzNILTBaQXVsWEh6Vm1iS1pmMUFncU5NSG0xSXFVZ0pxU3h0NG92TlJmMFJhUXJpZUtBM0NacXJtRks2SFZiNW56a293VzNRX183dDZfMEZpZDJjWllQRERzS2paSWJ6NmRYWVhVaXNRNGE0VTBIbmtrMTdyYzNVeW9Xc09nVU5jbEFSRVhCQl8waXo2ekpnbGU4RXp0UXRCanh1azhlMnIxdHRDdXZZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T20:08:00+00:00", "published_display": "14 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia: Vafseo Gains Traction, But It\u2019s Still A Show-Me Story (Rating Downgrade) (AKBA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPWWNiTXQ1UmkwQzNZd1JZVDRjMTB2UjRjVlhZTDc1NUFwYzBtc2wwSlFIbGVfQmY4YnRmYXZXNlJSYURXWXpoR0NZU0VhM2VtSk5nWE9TRHJHa0huS0JWampHODFfNkkwckNNd1JxM3ZpUTZiN1hkT2tQXy1mbDF3YTNSaXVGcURaTzJLWDBfY1Q1aEVsU01LT0ktZVBQRDgtN0plcVViRVlyeklwY2lWLTJjRXA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T11:30:30+00:00", "published_display": "14 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-reports-inducement-grants-200500888.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T20:05:00+00:00", "published_display": "02 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia awards 125,600 stock options to newly hired employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPNy1jWkJlQUhSR1Z4bW9IeFgwbVhVNXc3dDQ1Zkk5LTlNVlFCTlZ0Y21rbE1qWXE5MGNuZTZ3UjVQQTVpZVZVT3pxSEE3N1hibUZnMFpqNXUtNUZWUkVHMU5TSHBfWElmdGM3ZUlFb2hDVDVnWWtackRySVlmY3ZweUY1Q085SDlsNGdpbU1JTWFjYkVlQnNmUTc5eXZRSUdvWkxLdHc2VTBaRW4tN1kyZFA3Z0V4RVJMUm44S2V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Akebia stock rating on trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOck03TFFuZW56UGtPTzhzeEdpM2E3RkNFbVE3REVXTzJ6WW9Md3F0RF9IeDNfOUlRSFJMU0JNYzJrUGVUZURYbFNFUC1KWmhJZEk4a3Y1TEpTVmxuOU50eTkxN3NqZkF2X0dtVFR3NF83aXhkZktNYnFMT3U3amdrRjh0MEszQllWdXdjNmppSU1Fc2FDVWFxMzY3NDhLS0ZaYXEzeGNKdy1HUUphMXZrWGk2WGUzbFpWUnlmS3l3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPU1dBejhjUHFpZjgxRHRybXFEUEpnUlUzMnMyanJ3Um04WVVwVHBjMFRuLTJZa0xra0xpOUZzLWRjQ3IzaWE0R0hURUZvTmN6Qy1iRUEzYzZUU3ZOcU1TV2Z3SWdtVkxzR3N5LUI1cHBEQndlbFFsUURyanp5QVpGNEtibGxXaERrYXc1ZlJMN2JYUThwSzU3R1BrU3NJdVVFT3hJcmdVdE1xa0xJNzFvOTVXRU9rRXZF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-us-renal-care-125733849.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:57:33+00:00", "published_display": "30 Jun 2026 12:57", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/u-renal-care-akebia-announce-120000913.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNc3FhNUtOTkJlazFkRzFmbTJqQmpJdUN3LTk2a0lFU1o5NEZ1REJRSEc2R3Rza1NIMnVSY3dmRHY1V3RHU21hZ0pPZ0RCM1hfLUpQZkxxUmRTZUx0OVdRVzUwR0JSMXdQc1NFaERfbkxxRFJXNENFcTg3eWs1b3hYYURpcl84MWRkZlZVVTVEQWVsajVUQklaRVo2Mm03SjF2WTlV?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Akebia Therapeutics For: 29 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNjNGOU83MllmN2J6Q29pakZWZFBHMzJCdWRvclZUaF9hcGNmNWh3R3JoUUNLTE52Q01VdFo3YXc3WnFqZWhmZTdnQnZmSnNoMTJuM2JsamI3N3lHdFhCUmpsZGVDeHUtak05end6c0RBTHZQVk5taDdfaWR6Qko3SkdNbzNiMkdfZHRzazF1ZW41dVladFc1OHVjT0xKWEZXbDhF?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-30T00:45:39+00:00", "published_display": "30 Jun 2026 00:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZjNrYUYtU2E3cHZKaGRRdkRBSkNEVzFKZ0tRUUpza0c5QmpiOUlkMmc1cmJDcWpTVnUwQVVEUC1lU3dLcndSZE91dHRsQkFvUmktRjJFVFFPaWlNQlREUTg3NEJId3B4WFZrTDBEMGgzMnNFakVqNHZQUVBQOVFJMm5EWmFvYTd1bVVUaWlwRnNFbHlkLXRmX0RjZWp5V2R0UlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUHF3eW5FYV8yS3ppTzlfaDFrbW53T2NPSkZ4bjlXN2hwLTZHLUEwN0RyNjBsSm02ZlVlSnBHdEdCdHV5UFRUb2xaSnZNTnFXWGF0Ylo1ZHk3LVBlT2ZEdHdjWUMwSnFiS0hyS19XTGN0RHpQaDJ3dHJzUG9WeTZrNFZsdVJud0hSWUNkTUFaRWJqTERFa0EweUZHOXBNaGdmVHFYX3A3NW5oVTNmQnNWZENpcmoyWU5t?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbWlmZVJwbmJQZjVicGdpMDB1TGJ5WC11TXVtYlM4VFQ4d2V6WTdqSFhpRldXcFVjWW1oQVZ3X3BvYkNCLWE3NFE5eTRlV1AxYm81aVFCUFU0OU9nZFFnRGQyMmgwa1RQRmIySFR1dkpaMlVoX2VqXzlFOUdrdEtjeFplWlBIRTkwRVVWSmN1WTVxaG0tTHZrNWxYQjRxWksyNjN5dE96ZzRBVDFINzZhNEVocWpIak5L?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQOXJadTFTQ3dnMDhuZ1hnSHhSRWdFYl9qcGlIRzRFTHV2UHR2UVdLekRLMDE2VEtwOGFCVzlFWHFrUW5yX1lOVU1tUUQxdTBpZlpvd0xSd0xjQU9nbkJQZmdjLUt0T01XQTgweklNQ1pFQmhkZzVlT0lmT3RoSW9CdDNDYVdFOUdFRGtDUU9kdVBYLTlLUGpzWVhpQXc1akJBSy1EYzR6cjFGUzR4XzV0cEcxQTRRcjF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdWxCM3lVc2FKeXRtbmFZek9iNEVIRXJobHJWeXVwRElnLXROb0lDaVZoUTJWWnNyOUJpMmNCVVBxTFBXSEh6b1I0bmNuUlpBODVIUVZvTXpxSG1Wbk5NOGpXQnFsUlc3QUZ3VkxBRDB1VnZzZHFJS2pFd29Mdm9DLURtNVMzb1U5WmQ4U0FrZzJTU3haZjY3TnpCN1premRrV21VWWJHOUNtaGdiVVd3Y1Z2QWhseF82?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-secures-patent-covering-125501698.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:55:01+00:00", "published_display": "10 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Strengthens Vafseo\u00ae (vadadustat) Patent Portfolio", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-strengthens-vafseo-vadadustat-120000687.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T12:00:00+00:00", "published_display": "10 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near", "summary": "", "url": "https://finance.yahoo.com/m/51f1ba29-f7aa-32ce-b233-735535c738a7/akebia-therapeutics-sees.html", "source_name": "MarketBeat", "published_at": "2026-06-05T00:05:04+00:00", "published_display": "05 Jun 2026 00:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-present-2026-jefferies-120000735.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kidney disease-focused Akebia to present at NY healthcare conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeVpWLUJscUNvVUVTcWxZOVJJdzVIMUVBdTNaYTFsanREcHdWN1BJVzBpUGJCYzFxNnczY3FJMnBIWTNBR0xVc0l2V2F3TjRnNFM3T003SUVLa1BhdnlxY1pZOWJwOG04Zzl4Qy1ZS3lJNi1xaEhwOWxrWjkwcXJCc0dPcGxDVTlxMjRqeERTUnpQVnpLdXFLWEJEODlWMmY0YXo4Yi1iZ3lQbGI2ell1TUVfeF8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKBA - Akebia Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE04b3NPSGlhb29tcllsU3llQ3luS3hvRWVJQ3cybHJQWW1VY2E4VEx2R2lVcUctaUxpNlkycXFycmZsbUJVRVE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T15:48:34+00:00", "published_display": "27 May 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaE5BRE1Odk5CVFpTd1dsMlcteUpzd1pXcHZGTnlMa2R6eVlhaExxTGtUa3RsR1pjRUkzTnJoZTFVSHR2Y2NPR2dFa0JGR3VIZm5tM1FHd21qeEdLNGJPWHpUdWRWRnRGa2NHYVhQSnRHLXlDWi1MNVdvOFdkSU4zdjA5dWZramJXRUVLQnozMWpfbGU0cWNPaHZEQnNmaDRMY3VUNnpJbHBiUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPV1RsQTRmZ3Nkc2R4elpBQ0wzcHp0T295eXRkUGZZbm1WbC1rMU1iQ3JZZS1HcEc5RjZFTWZkWDVCTGhvV0VtYURMekY1bTBDMVU1TnVXZG5XSTBuX19iU2JISjBCRmhlZ0hxbHNMWkpGeEVmZXNKcmdFVDdzXzVmeFNaZkprV1VpNTJJNnhaSVBNMXR1N2ttWlZudk1qZ2VtTDhueA?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQU08ySHJGM0NidXFtUHJEZndzYU1STGd2LUwtNVdWc045eWVBR0ZKYXlEb1o2bm9TRzU3TUdVRGMtLWRxVUJyV1h0RjhsRWVwb2FUdVhval95TkIybFFEcEdjUkNSNjNBT2ZBSVlRbDBNaUZicjF2cWN4OVY1NVdvMnoxazZwSlliQ0tkbkd6eXNrRHQtc3dr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPR1NQY19HM1p5QnpOUzNILTBaQXVsWEh6Vm1iS1pmMUFncU5NSG0xSXFVZ0pxU3h0NG92TlJmMFJhUXJpZUtBM0NacXJtRks2SFZiNW56a293VzNRX183dDZfMEZpZDJjWllQRERzS2paSWJ6NmRYWVhVaXNRNGE0VTBIbmtrMTdyYzNVeW9Xc09nVU5jbEFSRVhCQl8waXo2ekpnbGU4RXp0UXRCanh1azhlMnIxdHRDdXZZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-14T20:08:00+00:00", "published_display": "14 Jul 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia: Vafseo Gains Traction, But It\u2019s Still A Show-Me Story (Rating Downgrade) (AKBA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPWWNiTXQ1UmkwQzNZd1JZVDRjMTB2UjRjVlhZTDc1NUFwYzBtc2wwSlFIbGVfQmY4YnRmYXZXNlJSYURXWXpoR0NZU0VhM2VtSk5nWE9TRHJHa0huS0JWampHODFfNkkwckNNd1JxM3ZpUTZiN1hkT2tQXy1mbDF3YTNSaXVGcURaTzJLWDBfY1Q1aEVsU01LT0ktZVBQRDgtN0plcVViRVlyeklwY2lWLTJjRXA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T11:30:30+00:00", "published_display": "14 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-reports-inducement-grants-200500888.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T20:05:00+00:00", "published_display": "02 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia awards 125,600 stock options to newly hired employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPNy1jWkJlQUhSR1Z4bW9IeFgwbVhVNXc3dDQ1Zkk5LTlNVlFCTlZ0Y21rbE1qWXE5MGNuZTZ3UjVQQTVpZVZVT3pxSEE3N1hibUZnMFpqNXUtNUZWUkVHMU5TSHBfWElmdGM3ZUlFb2hDVDVnWWtackRySVlmY3ZweUY1Q085SDlsNGdpbU1JTWFjYkVlQnNmUTc5eXZRSUdvWkxLdHc2VTBaRW4tN1kyZFA3Z0V4RVJMUm44S2V3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Akebia stock rating on trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOck03TFFuZW56UGtPTzhzeEdpM2E3RkNFbVE3REVXTzJ6WW9Md3F0RF9IeDNfOUlRSFJMU0JNYzJrUGVUZURYbFNFUC1KWmhJZEk4a3Y1TEpTVmxuOU50eTkxN3NqZkF2X0dtVFR3NF83aXhkZktNYnFMT3U3amdrRjh0MEszQllWdXdjNmppSU1Fc2FDVWFxMzY3NDhLS0ZaYXEzeGNKdy1HUUphMXZrWGk2WGUzbFpWUnlmS3l3?oc=5", "source_name": "Investing.com", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) CFO sells 56K shares in tax sell-to-cover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPU1dBejhjUHFpZjgxRHRybXFEUEpnUlUzMnMyanJ3Um04WVVwVHBjMFRuLTJZa0xra0xpOUZzLWRjQ3IzaWE0R0hURUZvTmN6Qy1iRUEzYzZUU3ZOcU1TV2Z3SWdtVkxzR3N5LUI1cHBEQndlbFFsUURyanp5QVpGNEtibGxXaERrYXc1ZlJMN2JYUThwSzU3R1BrU3NJdVVFT3hJcmdVdE1xa0xJNzFvOTVXRU9rRXZF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/akebia-therapeutics-us-renal-care-125733849.html", "source_name": "MT Newswires", "published_at": "2026-06-30T12:57:33+00:00", "published_display": "30 Jun 2026 12:57", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/u-renal-care-akebia-announce-120000913.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:00:00+00:00", "published_display": "30 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNc3FhNUtOTkJlazFkRzFmbTJqQmpJdUN3LTk2a0lFU1o5NEZ1REJRSEc2R3Rza1NIMnVSY3dmRHY1V3RHU21hZ0pPZ0RCM1hfLUpQZkxxUmRTZUx0OVdRVzUwR0JSMXdQc1NFaERfbkxxRFJXNENFcTg3eWs1b3hYYURpcl84MWRkZlZVVTVEQWVsajVUQklaRVo2Mm03SjF2WTlV?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Akebia Therapeutics For: 29 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPNjNGOU83MllmN2J6Q29pakZWZFBHMzJCdWRvclZUaF9hcGNmNWh3R3JoUUNLTE52Q01VdFo3YXc3WnFqZWhmZTdnQnZmSnNoMTJuM2JsamI3N3lHdFhCUmpsZGVDeHUtak05end6c0RBTHZQVk5taDdfaWR6Qko3SkdNbzNiMkdfZHRzazF1ZW41dVladFc1OHVjT0xKWEZXbDhF?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-06-30T00:45:39+00:00", "published_display": "30 Jun 2026 00:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) lists 56,019 shares after RSU vesting on 06/28/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZjNrYUYtU2E3cHZKaGRRdkRBSkNEVzFKZ0tRUUpza0c5QmpiOUlkMmc1cmJDcWpTVnUwQVVEUC1lU3dLcndSZE91dHRsQkFvUmktRjJFVFFPaWlNQlREUTg3NEJId3B4WFZrTDBEMGgzMnNFakVqNHZQUVBQOVFJMm5EWmFvYTd1bVVUaWlwRnNFbHlkLXRmX0RjZWp5V2R0UlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) grants RSUs and stock options to director Rogers", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUHF3eW5FYV8yS3ppTzlfaDFrbW53T2NPSkZ4bjlXN2hwLTZHLUEwN0RyNjBsSm02ZlVlSnBHdEdCdHV5UFRUb2xaSnZNTnFXWGF0Ylo1ZHk3LVBlT2ZEdHdjWUMwSnFiS0hyS19XTGN0RHpQaDJ3dHJzUG9WeTZrNFZsdVJud0hSWUNkTUFaRWJqTERFa0EweUZHOXBNaGdmVHFYX3A3NW5oVTNmQnNWZENpcmoyWU5t?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia (AKBA) director Cynthia Smith granted RSUs and options for board service", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbWlmZVJwbmJQZjVicGdpMDB1TGJ5WC11TXVtYlM4VFQ4d2V6WTdqSFhpRldXcFVjWW1oQVZ3X3BvYkNCLWE3NFE5eTRlV1AxYm81aVFCUFU0OU9nZFFnRGQyMmgwa1RQRmIySFR1dkpaMlVoX2VqXzlFOUdrdEtjeFplWlBIRTkwRVVWSmN1WTVxaG0tTHZrNWxYQjRxWksyNjN5dE96ZzRBVDFINzZhNEVocWpIak5L?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics (AKBA) awards RSUs and stock options to director Adams", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQOXJadTFTQ3dnMDhuZ1hnSHhSRWdFYl9qcGlIRzRFTHV2UHR2UVdLekRLMDE2VEtwOGFCVzlFWHFrUW5yX1lOVU1tUUQxdTBpZlpvd0xSd0xjQU9nbkJQZmdjLUt0T01XQTgweklNQ1pFQmhkZzVlT0lmT3RoSW9CdDNDYVdFOUdFRGtDUU9kdVBYLTlLUGpzWVhpQXc1akJBSy1EYzR6cjFGUzR4XzV0cEcxQTRRcjF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPdWxCM3lVc2FKeXRtbmFZek9iNEVIRXJobHJWeXVwRElnLXROb0lDaVZoUTJWWnNyOUJpMmNCVVBxTFBXSEh6b1I0bmNuUlpBODVIUVZvTXpxSG1Wbk5NOGpXQnFsUlc3QUZ3VkxBRDB1VnZzZHFJS2pFd29Mdm9DLURtNVMzb1U5WmQ4U0FrZzJTU3haZjY3TnpCN1premRrV21VWWJHOUNtaGdiVVd3Y1Z2QWhseF82?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-secures-patent-covering-125501698.html", "source_name": "MT Newswires", "published_at": "2026-06-10T12:55:01+00:00", "published_display": "10 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Strengthens Vafseo\u00ae (vadadustat) Patent Portfolio", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-strengthens-vafseo-vadadustat-120000687.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T12:00:00+00:00", "published_display": "10 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near", "summary": "", "url": "https://finance.yahoo.com/m/51f1ba29-f7aa-32ce-b233-735535c738a7/akebia-therapeutics-sees.html", "source_name": "MarketBeat", "published_at": "2026-06-05T00:05:04+00:00", "published_display": "05 Jun 2026 00:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/akebia-therapeutics-present-2026-jefferies-120000735.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T12:00:00+00:00", "published_display": "28 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kidney disease-focused Akebia to present at NY healthcare conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeVpWLUJscUNvVUVTcWxZOVJJdzVIMUVBdTNaYTFsanREcHdWN1BJVzBpUGJCYzFxNnczY3FJMnBIWTNBR0xVc0l2V2F3TjRnNFM3T003SUVLa1BhdnlxY1pZOWJwOG04Zzl4Qy1ZS3lJNi1xaEhwOWxrWjkwcXJCc0dPcGxDVTlxMjRqeERTUnpQVnpLdXFLWEJEODlWMmY0YXo4Yi1iZ3lQbGI2ell1TUVfeF8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKBA - Akebia Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE04b3NPSGlhb29tcllsU3llQ3luS3hvRWVJQ3cybHJQWW1VY2E4VEx2R2lVcUctaUxpNlkycXFycmZsbUJVRVE?oc=5", "source_name": "Finviz", "published_at": "2026-05-27T15:48:34+00:00", "published_display": "27 May 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNaE5BRE1Odk5CVFpTd1dsMlcteUpzd1pXcHZGTnlMa2R6eVlhaExxTGtUa3RsR1pjRUkzTnJoZTFVSHR2Y2NPR2dFa0JGR3VIZm5tM1FHd21qeEdLNGJPWHpUdWRWRnRGa2NHYVhQSnRHLXlDWi1MNVdvOFdkSU4zdjA5dWZramJXRUVLQnozMWpfbGU0cWNPaHZEQnNmaDRMY3VUNnpJbHBiUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPV1RsQTRmZ3Nkc2R4elpBQ0wzcHp0T295eXRkUGZZbm1WbC1rMU1iQ3JZZS1HcEc5RjZFTWZkWDVCTGhvV0VtYURMekY1bTBDMVU1TnVXZG5XSTBuX19iU2JISjBCRmhlZ0hxbHNMWkpGeEVmZXNKcmdFVDdzXzVmeFNaZkprV1VpNTJJNnhaSVBNMXR1N2ttWlZudk1qZ2VtTDhueA?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AKEBIA THERAPEUTICS ($AKBA) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQU08ySHJGM0NidXFtUHJEZndzYU1STGd2LUwtNVdWc045eWVBR0ZKYXlEb1o2bm9TRzU3TUdVRGMtLWRxVUJyV1h0RjhsRWVwb2FUdVhval95TkIybFFEcEdjUkNSNjNBT2ZBSVlRbDBNaUZicjF2cWN4OVY1NVdvMnoxazZwSlliQ0tkbkd6eXNrRHQtc3dr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 55, "total_relevant": 25, "sentiment_summary": {"positive": 2, "negative": 0, "neutral": 23, "score": 51, "total": 25, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 87, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.9, "count": 1}], "positive_events": 2, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 1.4, "latest_week": "2026-07-10", "one_week_move": 12.9, "four_week_move": 51.4, "twelve_week_move": -0.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.384002, "market_dynamics_buy_signal": false, "relative_strength": -38.250411, "fair_value_gap": -20.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.6628, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.9% over one week, +51.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "GlobeNewswire", "count": 4}, {"label": "Market source", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Seeking Alpha", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 25}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 4}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "25", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.9% over one week, +51.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed"}], "updated_at": "2026-07-16T14:29:28.055284+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}